China’s State Council issued new Anti-Monopoly Guidelines for the Pharmaceutical Sector (the “Guidelines”) effective January 24, 2025. The Guidelines provide a comprehensive framework for the State Administration for Market Regulation (“SAMR”), the Chinese antitrust regulator, to analyze potential anticompetitive behavior across the pharmaceuticalsector, including some types of conduct SAMR has not previously addressed….
By: Jones Day
By: Jones Day
